Abstract

A method for purifying a composition, the method including a step of dissolving a composition including a compound represented by Formula (1) [in Formula (1), R1 represents —N(R2)—R2 (R2 represents a C1 to C4 alkyl group), each R3 and R4 represents a C3 to C8 alkanediyl group, R5 represents a hydroxyl group, R6 represents —R7—OH (R7 represents a C4 to C12 alkanediyl group) or a hydrogen atom, and n represents an integer of 0 or 1] in an aqueous layer to perform liquid-liquid extraction, in which an oil layer used for the liquid-liquid extraction includes one or more kinds of liquids selected from the group consisting of a ketone-based liquid, an ester-based liquid, and an ether-based liquid, all of which have a solubility parameter (SP value) of 14.8 to 20.5 (MPa1/2).

IPC Classes  ?

• C07C 219/20 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
• A61K 9/51 - Nanocapsules
• B01D 11/04 - Solvent extraction of solutions which are liquid
• C07C 213/10 - SeparationPurificationStabilisationUse of additives
• C07C 227/40 - SeparationPurification
• C07C 229/30 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated

Abstract

Task of the present disclosure is to provide a solanaceous plant and cells thereof and a method for producing the solanaceous plant where the plant has inhibitory properties against infection by a virus of genus Begomovirus causing tomato yellow leaf curl symptoms, propagation of the infected virus, and/or expression of infection symptoms, and the plant is resistant to the virus. The task is solved by providing a solanaceous plant having a mutation in at least one gene selected from a group consisting of DCL3 gene which is silencing associated dicer gene, 4CL06 gene which is 4-coumarate-CoA ligase gene, RLK2 gene which is receptor-like kinase gene, and genes homologous thereto. The mutation either inhibits the expression of the mutated gene or makes a protein encoded by the mutated gene to be non-functional for the virus, and the plant has virus resistance against the above-mentioned virus.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

It is an object of the present invention to provide a novel technique of regulating mRNA splicing. Provided is an artificial RNA molecule comprising (a) a polynucleotide potentially having a secondary structure represented by the formula (I), wherein N1 to N25 each independently represents A, C, G, or U, or a polynucleotide in which 1 to 3 bases are substituted, deleted, or added among 7 bases on the 3′ side of the polynucleotide potentially having the secondary structure represented by the formula (I); and (b) a pre-mRNA targeting polynucleotide comprising a sequence complementary to a target sequence that is a portion of a pre-mRNA; wherein the (a) and the (b) are arranged from the 5′ side to the 3′ side in this order. It is an object of the present invention to provide a novel technique of regulating mRNA splicing. Provided is an artificial RNA molecule comprising (a) a polynucleotide potentially having a secondary structure represented by the formula (I), wherein N1 to N25 each independently represents A, C, G, or U, or a polynucleotide in which 1 to 3 bases are substituted, deleted, or added among 7 bases on the 3′ side of the polynucleotide potentially having the secondary structure represented by the formula (I); and (b) a pre-mRNA targeting polynucleotide comprising a sequence complementary to a target sequence that is a portion of a pre-mRNA; wherein the (a) and the (b) are arranged from the 5′ side to the 3′ side in this order.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

To provide an information processing system and the like that learn in such a way as to effectively improve performance of an agent for a task requiring a plurality of steps. An information processing system according to the present disclosure includes: an agent configured to output a sequence of a plurality of actions including an action of outputting a command to an external tool in response to a user query; a feedback acquisition unit configured to acquire final feedback on the output sequence of the plurality of actions; and a parameter update unit configured to update a parameter of a model of the agent by using the feedback.

IPC Classes  ?

• G06F 9/448 - Execution paradigms, e.g. implementations of programming paradigms
• G06F 40/289 - Phrasal analysis, e.g. finite state techniques or chunking
• G06F 40/40 - Processing or translation of natural language

Abstract

To provide a treatment plan evaluation system capable of supporting determination when a treatment plan is selected. A treatment plan evaluation system 1 that evaluates a treatment plan of a radiotherapy system RTS has a function of comparing a selected treatment plan with a record in which adoption of a past treatment plan has been determined, and provides a comparison result between the selected treatment plan and the record.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

A design device (100) includes: a beam generator (152) that repeatedly generates a plurality of new beams branching from a node closer to the leading end of an existing beam while changing at least one of a beam length, the number of branches, or a rotation angle about the axis of the existing beam on the basis of a preset rule so that a plurality of beams included in the network structure of a porous structure are generated in the design space acquired by an acquirer (151); and a node joiner (153) that selects a plurality of nodes that is not directly connected to each other through a beam, among the plurality of nodes generated by the beam generator (152), to join the selected nodes to generate a single node on the basis of a preset rule.

IPC Classes  ?

• G06F 30/18 - Network design, e.g. design based on topological or interconnect aspects of utility systems, piping, heating ventilation air conditioning [HVAC] or cabling

Abstract

This animal behavior recording device is provided with a processing unit which acquires animal behavior information, that is, information indicating the behavior of an animal, acquires animal position information, that is, information indicating the positions where the animal is present, estimates the behavior of the animal on the basis of the animal behavior information and the animal position information, and records the behavior in time series. Acceleration data acquired from an acceleration sensor disposed on the animal and/or angular velocity data acquired from an angular velocity sensor disposed on the animal can be used as the animal behavior information, and the processing unit is capable of estimating the behavior of the animal on the basis of one of the animal behavior information and the animal position information and correcting the estimated behavior by using the other information.

IPC Classes  ?

• A01K 11/00 - Marking of animals
• A01K 27/00 - Leads or collars, e.g. for dogs
• A01K 29/00 - Other apparatus for animal husbandry

Abstract

This field effect transistor has: a substrate having a (111) surface, the substrate comprising a group IV semiconductor doped with a first electroconductivity type; a core-shell nanowire including a core nanowire connected to the (111) surface of the substrate, the core nanowire comprising a group III-V compound semiconductor doped with a second electroconductivity type different from the first electroconductivity type, and a shell layer disposed so as to cover the core nanowire, the shell layer comprising a group III-V compound semiconductor doped with the first electroconductivity type; a first electrode electrically connected to the shell layer; a second electrode electrically connected to the substrate; and a gate electrode for inducing a field at the joining interface between the substrate and the core nanowire and at the shell layer.

IPC Classes  ?

• H10D 48/00 - Individual devices not covered by groups

Abstract

The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X  (I) The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X  (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-  (A) The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (wherein R11 and R12 each independently represent a linear or branched C1-15 alkyl group; c represents an integer of 1 to 7; and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3 and R4 each independently represent a C1-4 alkyl group or a C2-4 alkenyl group, in which R3 and R4 may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-(A) —(CH2)d-N(R3)(R4) (B) [Chem. 1] (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X  (I) (R11)(R12)HC—(CH2)c-(CO—O)—(CH2)e-  (A) —(CH2)d—N(R3)(R4)  (B)

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
• A61K 9/51 - Nanocapsules
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

A carbon dioxide immobilization method includes: impregnating a cured cement body (10) with a carbon dioxide absorbing liquid containing a carbon dioxide absorbent (20) to obtain a cured cement body (1) for carbon dioxide immobilization, in which the carbon dioxide absorbent (20) is supported within the cured cement body (10); and bringing the cured cement body (1) for carbon dioxide immobilization into contact with air to immobilize carbon dioxide contained in the air in the cured cement body (1) for carbon dioxide immobilization.

IPC Classes  ?

• B01D 53/62 - Carbon oxides
• B01D 53/81 - Solid phase processes
• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• C04B 41/45 - Coating or impregnating
• C04B 41/46 - Coating or impregnating with organic materials
• C04B 41/62 - Coating or impregnating with organic materials
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone

Abstract

An optical device includes a substrate having a first region and a second region in a surface thereof, a first waveguide for inputting light, and at least one second waveguide for outputting light. The second region surrounds the first region. The first waveguide and the second waveguide are optically coupled to the first region. The substrate includes a first layer and a second layer sequentially stacked one on top of the other in the first region. The second layer has a plurality of holes. A depth of each of the holes is half of a thickness of the second layer or smaller. The substrate does not have the second layer and has the first layer in the second region.

IPC Classes  ?

• G02B 6/124 - Geodesic lenses or integrated gratings
• G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind

Abstract

A composite comprising: a skeleton having a porous structure and containing a crystalline SiO2 compound; and a fine particles including a metal oxide fine particles or a metal fine particle existing within the skeleton.

IPC Classes  ?

• B01J 29/06 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof
• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 35/23 - Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/45 - Nanoparticles
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 37/02 - Crystalline silica-polymorphs, e.g. silicalites

Abstract

A humanized antibody or a functional fragment thereof binding to a human-derived Eval protein, an antibody-drug conjugate comprising the humanized antibody or a functional fragment thereof, or a chimeric antigen receptor comprising an antibody or a functional fragment thereof binding to a human-derived Eval protein.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A latent heat storage particle that comprises a core particle and a coating part covering at least a part of the surface of the core particle, wherein: the core particle is composed of an element selected from the group consisting of Al, Mg, Si, Ti, Fe, Ni, Cu, Zn, Sn, Sb, Ga, In, Bi, Pb and Cd or an alloy or a compound mainly composed of the same and has a melting point of 100° C. or higher; the coating part is composed of one or more selected from the group consisting of an element different from the component of the core particle, an alloy and an inorganic compound containing the element and a mixture thereof, which does not undergo a chemical reaction with the core particle in the temperature range of the operating temperature; and at least a part of the coating part is in a particulate shape.

IPC Classes  ?

• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
• B22F 1/16 - Metallic particles coated with a non-metal

Abstract

An object is to provide a mechanochemical-reaction additive that can be handled in the air, can be easily synthesized, can be used in a mechanochemical reaction to increase the activity of the mechanochemical reaction, and can be applied to wide-ranging substrates under mild conditions. A solving means provided is a mechanochemical-reaction additive including at least a ligand compound (Lx) or salt thereof, wherein the ligand compound (Lx) is one or more of a phosphorus-based compound, a bipyridine-based compound, and an N-heterocyclic carbene-based compound, and the ligand compound (Lx) intramolecularly has a polymer chain and the polymer chain is one or more of polyether, polyamide, polyester, and polyurethane.

IPC Classes  ?

• C08G 65/335 - Polymers modified by chemical after-treatment with organic compounds containing phosphorus
• C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen

Abstract

Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition comprises a retinoic acid receptor (RAR) agonist.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/203 - Retinoic acids
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A catalyst structure for synthesis gas production is used to produce a synthesis gas that includes carbon monoxide and hydrogen. The structure includes a carrier with a porous structure that comprises a zeolite-type compound; first catalyst particles that contain at least one iron-group element selected from the group consisting of nickel, iron, and cobalt; and a second catalyst that contains at least one transition metal element with redox capacity. The carrier includes, inside thereof, mutually communicating passages; the first catalyst particles are present at least in the passages of the carrier; and the second catalyst is present at least in the interior or on an outer surface of the carrier.

IPC Classes  ?

• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 35/45 - Nanoparticles
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

The embolic agent according to the present invention includes as an active ingredient a copolymer of a cationic functional group-containing monomer and an aromatic group-containing monomer, the copolymer having at least a part thereof a structure represented by general formula (I) (in the formula, R11 and R12 are hydrogen atoms or alkyl groups having 1 to 20 carbon atoms which may have a substituent, and satisfy a relational formula: R11=R12; Y11 and Y12 are each independently a single bond or an alkylene group having 1 to 20 carbon atoms; Ar11 is an aromatic hydrocarbon group having 6 to 16 carbon atoms which may have a substituent; X11 is an ammonium group or an amino group; and n11 is an integer of 10 to 1,000.) The embolic agent according to the present invention includes as an active ingredient a copolymer of a cationic functional group-containing monomer and an aromatic group-containing monomer, the copolymer having at least a part thereof a structure represented by general formula (I) (in the formula, R11 and R12 are hydrogen atoms or alkyl groups having 1 to 20 carbon atoms which may have a substituent, and satisfy a relational formula: R11=R12; Y11 and Y12 are each independently a single bond or an alkylene group having 1 to 20 carbon atoms; Ar11 is an aromatic hydrocarbon group having 6 to 16 carbon atoms which may have a substituent; X11 is an ammonium group or an amino group; and n11 is an integer of 10 to 1,000.)

IPC Classes  ?

• A61L 24/06 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

A reaction-path search system calculates a reaction path in a structure formed of multiple atoms as a change in a structure represented by a positional relationship of the multiple atoms. The reaction-path search system including: a structural change calculation unit which calculates a change in the structure in which a result of a function FAFIR(Q) is at the minimum; a differential coefficient calculation unit which calculates at least one of a second differential coefficient b or a third differential coefficient a of E(Q) at the positions of the multiple atoms; and an equilibrium state change calculation unit which causes the structural change calculation unit to calculate the change in the structure in transition from the first equilibrium state to the second equilibrium state, prior to the other fragment pairs with lower priority than the fragment pair with higher priority based on the magnitude of a and b.

IPC Classes  ?

• G16C 20/40 - Searching chemical structures or physicochemical data
• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes

Abstract

A reservoir device receives input of time series sensor data measured in a predetermined process and outputs a reservoir feature value based on a result of processing using an input weight multiplier and a connection weight multiplier, in which the input weight multiplier weights the input sensor data, using a value determined by a periodic function as an input weight, and the connection weight multiplier performs weighted addition of data indicating states of nodes, using a value determined by a periodic function as a connection weight between two nodes among the nodes.

IPC Classes  ?

• G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]

Abstract

The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (GDNF) is not present, the neurite outgrowth promoter containing at least one protein selected from the group consisting of: GDNF family receptor α1 (GFRα1): GFRα1 mutants having an amino acid sequence that has at least 90% sequence identity with the amino acid sequence of GFRα1, the GFRα1 mutants having neurite outgrowth activity; fusion proteins that have neurite outgrowth activity and that are obtained by fusing GFRα1 or a GFRα1 mutant with another peptide; and chemically modified proteins that have neurite outgrowth activity and that are obtained by chemically modifying one or a plurality of amino acid residues in GFRα1, a GFRα1 mutant, or a fusion protein. The present invention also provides a pharmaceutical composition for inducing nerve regeneration.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators

Abstract

The present invention provides a pharmaceutical composition comprising a compound exhibiting coronavirus proliferation inhibitory activity. The present invention provides a pharmaceutical composition comprising a compound exhibiting coronavirus proliferation inhibitory activity. The present invention provides a pharmaceutical composition comprising a compound exhibiting coronavirus proliferation inhibitory activity. A pharmaceutical composition comprising a compound represented by the formula: wherein Y is N; R1 is substituted or unsubstituted aromatic heterocyclyl; R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl; R3 is substituted or unsubstituted aromatic heterocyclyl; —X— is —NH—; m is 0 or 1; R5a is a hydrogen atom; R5b is a hydrogen atom; n is 1; R4a is a hydrogen atom; and R4b is a hydrogen atom, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A metal porous body includes a framework having a three-dimensional mesh structure, wherein the framework includes a plurality of columnar supporting portions and a node portion that connects the plurality of columnar supporting portions, the framework is provided with a plurality of opening holes opened in a surface of the framework, and the framework contains at least one selected from a group consisting of nickel, cobalt, iron, tin, copper, and chromium.

IPC Classes  ?

• C25B 11/031 - Porous electrodes
• C25B 11/046 - Alloys

Abstract

An optical filter includes a first multiplexer having a first input end, a second input end, a first output end, and a second output end, a first waveguide optically coupled to the first input end, a second waveguide optically coupled to the second input end, a third waveguide optically coupled to the first output end, a fourth waveguide optically coupled to the second output end, and a ring resonator optically coupled to the third waveguide and the fourth waveguide.

IPC Classes  ?

• H01S 3/083 - Ring lasers
• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• H01S 3/00 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range

Abstract

The present disclosure is directed to a plasma measurement device comprising: a laser light source configured to apply laser light to plasma; and a spectrum measurement unit configured to receive scattered light from the plasma and measure a wavelength spectrum of the scattered light; and an arithmetic unit configured to calculate an electron temperature and an electron density of the plasma, based on the measured wavelength spectrum, wherein the spectrum measurement unit includes a spectroscope having an incidence slit, the incidence slit including: two blades movable in X-direction in an XY-plane perpendicular to a traveling direction of the scattered light; and at least one blade movable in Y-direction perpendicular to X-direction, edges of at least three of the blades forming a slit shape, thereby relaxing the structural constraints for plasma measurement and performing measurement with higher accuracy.

IPC Classes  ?

• G01J 3/443 - Emission spectrometry
• G01J 3/44 - Raman spectrometryScattering spectrometry

Abstract

A method of manufacturing an optical filter is a method of manufacturing an optical filter including two or more waveguides having four or more sections in which a number of modes of light propagating through the four or more sections is two or more. The method includes designing lengths of the four or more sections, and forming the two or more waveguides based on the lengths of the four or more sections. The designing includes designing the lengths of the four or more sections based on differentiation of propagation constants of the sections with respect to a temperature and widths of the sections.

IPC Classes  ?

• G02B 5/28 - Interference filters
• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,

Abstract

A method for producing a cyclic peptide, comprising using a penicillin-binding protein-type thioesterase (PBP-type TE) or a tyrocidine synthase TycC thioesterase domain (TycC-TE) as a catalyst, wherein a diol as a leaving group is attached to a carboxyl group of a C-terminal residue of a substrate; and a method for producing a peptide serving as the substrate using a solid phase carrying a diol.

IPC Classes  ?

• C07K 7/50 - Cyclic peptides containing at least one abnormal peptide link
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)

Abstract

A pharmaceutical composition for treating peripheral nerve injury, includes a substance that inhibits the formation of neutrophil extracellular traps (NETs) outside the parenchyma of injured peripheral nerves, for example, a substance that inhibits the accumulation of neutrophils in injured peripheral nerves, a substance that suppresses the expression or inhibits the function of macrophage migration inhibitory factor (MIF), etc. Further provided is a method for evaluating the peripheral nerve regeneration-promoting activity of a test substance using, as an indicator, the activity to inhibit the formation of NETs outside the parenchyma of injured peripheral nerves, for example, the activity to inhibit the accumulation of neutrophils in injured peripheral nerves, the activity to suppress the expression of MIF or the activity to inhibit the function thereof, etc.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/42 - Oxazoles
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/46 - Hydrolases (3)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

A method according to the present disclosure is a method of manufacturing a multiplexer/demultiplexer including a substrate, a first port for inputting light, and a second port for outputting light, the first port and the second port being provided in the substrate. The method includes designing positions of a plurality of holes such that three adjacent holes among the plurality of holes are arranged in a triangle lattice, and forming the plurality of holes in a surface of the substrate.

IPC Classes  ?

• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,

Abstract

The present disclosure provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. The present disclosure further provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor. The present disclosure also provides an anti-PD-1 antibody capable of repeated administration even to animals other than rat. An anti-PD-1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 164), CDR2 having the amino acid sequence of GVS and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 165) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 166), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 167) and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 168) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above-described anti-PD-1 antibody as an active ingredient. A method for preparing the anti-PD-1 antibody is also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention provides a method for combusting of a hybrid rocket fuel, comprising supplying aqueous solution of hydrogen peroxide to a combustion chamber provided with a solid fuel, wherein a concentration of hydrogen peroxide in the aqueous solution of hydrogen peroxide is less than 65% by weight, and the method for combusting comprises at least one of: (i) supplying oxygen and the aqueous solution of hydrogen peroxide to the combustion chamber, and (ii) heating the aqueous solution of hydrogen peroxide before supplying the aqueous solution of hydrogen peroxide to the combustion chamber.

IPC Classes  ?

• F02K 9/72 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant thereforControl thereof using liquid and solid propellants, i.e. hybrid rocket-engine plants
• F23K 5/22 - Vaporising devices

Abstract

It is an object to provide an optical filter, a method of manufacturing an optical filter, a method of designing, a design apparatus, and a program for designing non-transitory computer-readable recording medium which can suppress both the temperature dependency and the waveguide length. An optical filter includes three or more waveguides, and a plurality of sections provided in the three or more waveguides, respectively. Modes of light propagating through the sections of the three or more waveguides are different from each other.

IPC Classes  ?

• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• G02B 5/20 - Filters
• G02B 5/28 - Interference filters
• G02B 6/27 - Optical coupling means with polarisation selective and adjusting means

Abstract

A method for generating spectral data according to the present invention involves generating spectral data pertaining to a microparticle sample that includes at least one microparticle, wherein: the method includes a step for acquiring a measurement spectrum from microparticles disposed within a through-hole in a substrate; the through-hole has an inclined structure in which the width continuously decreases from one surface of the substrate toward the other surface thereof; at least part of the inner surface of the through-hole is configured from a metal that exhibits plasmon resonance; and in the step for acquiring the measurement spectrum, the measurement spectrum is acquired while the interior of the through-hole is irradiated with light.

IPC Classes  ?

• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

The present invention provides an antiviral agent formed from a compound represented by general formula (A-1) or (A-2) shown below [wherein in the formulas, R1 represents O, S, Se or =N—OR11; R2 represents O, S, Se or ═N—OR11; R3 represents —O—R12, —S—R13 or a guanidino group; R11 represents H, an alkyl group or an aryl group; R12 and R13 each independently represent an alkyl group or an aryl group; R4 represents H, —CO—R14 or —O—P(OH)(═O)—O—R15; R14 and R15 each independently represent an alkyl group or an aryl group; R5 and R6 each independently represent H or —CO—R16; and R16 represents an alkyl group of 1 to 6 carbon atoms or an aryl group], a salt of the compound, or a solvate of the compound or salt.

IPC Classes  ?

• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61P 31/14 - Antivirals for RNA viruses
• C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical

Abstract

An object is to prevent eavesdropping in quantum key distribution. A synchronization signal reception device receives a synchronization signal that is an optical signal for defining a timing at which a quantum signal is detected, and outputs a reference signal corresponding to the synchronization signal. A clock signal generation unit generates a clock signal in response to the reference signal. A photon detection device detects a photon of the quantum signal in response to the clock signal. A timing of the clock signal randomly changes within a predetermined range.

IPC Classes  ?

• H04L 9/08 - Key distribution
• H04B 10/70 - Photonic quantum communication
• H04L 9/12 - Transmitting and receiving encryption devices synchronised or initially set up in a particular manner

Abstract

The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Provided is a compound represented by Formula (I): The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Provided is a compound represented by Formula (I): wherein carbon atom a and carbon atom b are each a carbon atom constituting ring A, the ring A is substituted aromatic carbocycle or the like, R1 is substituted or unsubstituted aromatic heterocyclyl or the like, R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl or the like, m is 1 or the like, R5as are each independently a hydrogen atom or the like, R5bs are each independently a hydrogen atom or the like, n is 1 or the like, R4a is a hydrogen atom or the like, and R4a is a hydrogen atom or the like. Alternatively, provided is a pharmaceutically acceptable salt of the compound.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61P 31/14 - Antivirals for RNA viruses
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 487/08 - Bridged systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

A common-mode voltage canceller cancels a common-mode voltage that is generated in accompaniment with operation of an inverter that converts direct-current power to alternating-current power. The common-mode voltage canceller includes a common-mode transformer that generates a cancellation voltage that has a polarity reverse to the common-mode voltage. The common-mode transformer is disposed on a direct-current power line that supplies the direct-current power to the inverter.

IPC Classes  ?

• H02M 1/12 - Arrangements for reducing harmonics from AC input or output
• H02M 1/15 - Arrangements for reducing ripples from DC input or output using active elements
• H02M 1/44 - Circuits or arrangements for compensating for electromagnetic interference in converters or inverters

Abstract

It is provided an area design proposal system for proposing equipment placement and configuration of a regional energy system comprising: a long-term operation optimization module configured to output an optimum solution for the equipment placement and configuration through use of a long-term operation algorithm with input of parameters including energy equipment information, vehicle equipment information, an energy equipment introduction cost, a vehicle introduction cost, and an initial cost upper limit amount; and a short-term operation optimization module configured to calculate short-term operation evaluation results, which are evaluation results of the equipment placement and configuration, through use of a short-term operation algorithm with input of the output from the long-term operation optimization module and short-term environmental fluctuation factors, and wherein the long-term operation optimization module is configured to optimize the equipment placement and configuration with input of the short-term operation evaluation results.

IPC Classes  ?

• G06F 30/18 - Network design, e.g. design based on topological or interconnect aspects of utility systems, piping, heating ventilation air conditioning [HVAC] or cabling

Abstract

Provided is a spatial light modulation device which can be driven at a frame rate higher than that of a two-dimensional light modulator. A spatial light modulation device (10) includes a two-dimensional light modulator (11) including a cell group (C) in which cells are arranged in a matrix manner, and a scanning optical system (cylindrical lens 14, scanning mirror 16, objective lens 17). The scanning optical system repeatedly carries out a first conversion step (S11) of converting a two-dimensional beam (L21) into a one-dimensional beam (L11), a modulation step (S12) of generating a spatially modulated one-dimensional beam (L12), and a second conversion step (S13) of converting the modulated one-dimensional beam (L12) into a two-dimensional beam (L22), while changing a column of the cell group (C) which the one-dimensional beam (L11) is caused to enter in the modulation step (S12).

IPC Classes  ?

• G02B 26/10 - Scanning systems
• G02B 26/08 - Optical devices or arrangements for the control of light using movable or deformable optical elements for controlling the direction of light

Abstract

It is desirable to provide a novel biomaterial and the like for tendon repair. Provided is a biomaterial for tendon repair containing a hydrogel formed by means of a cross-linking reaction between a reactive group A and a reactive group B, wherein the hydrogel contains a water-soluble polymer having the reactive group A, and mesenchymal stem cells having the reactive group B.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/20 - Polysaccharides
• A61L 27/52 - Hydrogels or hydrocolloids

Abstract

A phase modulator calibration method includes steps of: providing a first delay interferometer to be used as a phase calibration reference and a second delay interferometer in which a phase modulator to be calibrated is installed in an optical path; for each of the first and second delay interferometers, measuring a delay time based on a time interval between pulses split from one input pulse and synchronizing the delay time with a cycle of a transmission clock; for the first delay interferometer, adjusting a phase difference so that input continuous-wave laser light produces an intensity-enhancing interference at an output; and determining the control signal with a calibration circuitry formed by connecting the first delay interferometer as a front stage and the second delay interferometer as a rear stage in a cascaded manner.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference

Abstract

Provided is a sulfide solid electrolyte that has a novel crystal structure and exhibits an ionic conductivity, the sulfide solid electrolyte containing a lithium atom, a phosphorus atom, a sulfur atom, and at least one kind of halogen atom selected from a chlorine atom and a bromine atom, and having a specific diffraction peak in powdery X-ray diffractometry using CuKα line, and a method for producing a sulfide solid electrolyte, the method including mixing a solvent 1 having a heteroatom and a raw material 1 containing specific atoms to prepare a mixture, preparing a solution that contains a raw material 2 containing a halogen atom and a solvent 2 having a heteroatom, mixing the mixture and the solution to prepare a fluid, and heating the fluid.

IPC Classes  ?

• H01M 10/0562 - Solid materials
• C01B 25/14 - Sulfur, selenium, or tellurium compounds of phosphorus

Abstract

Provided are a lignin degradation catalyst that exhibits excellent lignin degradability and that is readily separated after degradation reaction, a method for producing the catalyst, and a method for degrading lignin. The lignin degradation catalyst according to the present invention contains a substrate and at least one metal compound immobilized on the substrate, wherein the at least one metal compound contains a copper compound. The method for producing a lignin degradation catalyst according to the present invention includes the step of brining a porous copper substrate into contact with a solution containing an oxidant to obtain a substrate having a copper compound immobilized thereon, or the step of subjecting a porous copper substrate to electro-oxidation to obtain a substrate having a copper compound immobilized thereon.

IPC Classes  ?

• B01J 23/889 - Manganese, technetium or rhenium
• B01J 23/72 - Copper
• B01J 23/755 - Nickel
• B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
• B01J 23/94 - Regeneration or reactivation of catalysts comprising metals, oxides or hydroxides of the iron group metals or copper
• B01J 35/56 - Foraminous structures having flow-through passages or channels, e.g. grids or three-dimensional monoliths
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• B01J 38/02 - Heat treatment
• C07C 41/01 - Preparation of ethers
• C07C 45/32 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen
• C07C 51/21 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with molecular oxygen

Abstract

A treatment planning system is configured to create a treatment planning for radiotherapy and includes a processing device and a memory. The memory stores a plurality of calculation models, and the processing device uses at least two of the plurality of calculation models to calculate calculation values of biological effect indices representing an effect of radiotherapy with respect to a condition for radiotherapy, and searches for the condition so that at least two of the calculation values to be calculated approach a predetermined target value.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

There are provided a method for detecting amyloid-β bound to a brain-neuronal-cell-derived exosome in blood, the method including: a step of binding amyloid-β bound to the brain-neuronal-cell-derived exosome in blood to an amyloid-β-specific binding substance that specifically binds to amyloid-β, labeled with a nucleic acid fragment; and a step of detecting the amyloid-β-specific binding substance, and a method for evaluating an accumulation level of amyloid-β in a brain, the method including: a step of detecting amyloid-β bound to the brain-neuronal-cell-derived exosome in blood; and a step of evaluating an accumulation level of amyloid-β in a brain based on the detected amount of the amyloid-β.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Polyoxyethylene derivatives represented by the following formula (1) provided by the present invention: Polyoxyethylene derivatives represented by the following formula (1) provided by the present invention: Polyoxyethylene derivatives represented by the following formula (1) provided by the present invention: wherein the symbols in the formula are as defined in the specification, can form conjugates with polypeptide that can be degraded over a long time under physiological conditions to release the polypeptide.

IPC Classes  ?

• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C12N 9/22 - Ribonucleases

Abstract

The present disclosure is directed to an ignition device including a housing, a bulk fuel, and at least two lead wires as electrodes. The bulk fuel is made of a plastic material, such as polylactic acid (PLA) or epoxy resin. The bulk fuel contains an internally dispersed powdery conductive material, thereby obtaining a conductive solid fuel. One end of the lead wire is partially embedded in the bulk fuel. The other end of the lead wire is connected to a power source. A portion of the bulk fuel is gasified by energizing the lead wire, and the gasified fuel is combusted by reaction with an oxidant.

IPC Classes  ?

• F02K 9/95 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant thereforControl thereof characterised by starting or ignition means or arrangements
• F02K 9/08 - Rocket-engine plants, i.e. plants carrying both fuel and oxidant thereforControl thereof using solid propellants

Abstract

The present invention provides lipid nanoparticles that contain a pH-sensitive cationic lipid and a polyalkylene glycol-modified lipid. The pH-sensitive cationic lipid fraction of the total lipids that constitute the lipid nanoparticles is 10-25 mol %, the polyalkylene glycol-modified lipid fraction of the total lipids that constitute the lipid nanoparticles is 0.5-1.75 mol %, and the number average particle size of the lipid nanoparticles is at least 150 nm.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders

Abstract

A dispersion for an X-ray target in which gold nanoparticles and sodium alginate or a calcium phosphate-based bone reinforcing material are dispersed, in which the gold nanoparticles are in contact with the sodium alginate or the calcium phosphate-based bone reinforcing material.

IPC Classes  ?

• A61K 49/04 - X-ray contrast preparations

Abstract

[Problem] To provide an ultrasonic physical properties measurement device that suppresses the generation of a secondary flow inside a cylinder, is more portable, and can suppress changes in physical properties. [Problem] To provide an ultrasonic physical properties measurement device that suppresses the generation of a secondary flow inside a cylinder, is more portable, and can suppress changes in physical properties. [Solution] An ultrasonic physical properties measurement device 1 that: uses ultrasonic waves to measure the flow velocity profile of fluids that flow inside a cylinder 2, by rotating the cylinder 2 backwards and forwards in a fixed cycle; and calculates the physical properties of fluid from the flow velocity profile. The cylinder 2: has an upper end surface 21 and lower end surface 22 that are penetrated such that fluid can flow therethrough; and comprises a rotation mechanism 3 that supports all or part of the cylinder 2 in a state of immersion in the fluid and rotates the cylinder 2 backwards and forwards.

IPC Classes  ?

• G01F 1/66 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters

Abstract

A cell mass-forming member that is capable of easily forming a cell mass and superior in industrial mass productivity; a culture container equipped with the cell mass-forming member; a method for producing cultured cells using the cell mass-forming member; and cultured cells with a cell mass-forming member that are equipped with the cell mass-forming member. The cell mass-forming member has a base material, an adhesion inhibition area and a cell adhesion area are formed on the surface of the base material; a micro-concavo-convex structure area including a plurality of convex portions is formed in the cell adhesion area; and a hydrophilic coating layer is formed on both the adhesion inhibition area and the cell adhesion area. The culture container and the cultured cells with a cell mass-forming member are equipped with the cell mass-forming member. The method for producing cultured cells includes using the cell mass-forming member.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/09 - Tumour cells

Abstract

An object of the present invention is to provide an industrially easily available hatching factor on Globodera pallida larvae, a control agent and a control method using the same. The Globodera pallida control agent of the present invention contains, as an active ingredient, at least one selected from a compound of formula (I) below, a stereoisomer thereof, and a salt thereof [wherein Ar represents a substituted or unsubstituted phenyl group or the like; R1 each independently represents a group such as a substituted or unsubstituted C1 to 6 alkyl group and a substituted or unsubstituted C2 to 6 alkenyl group; R2 represents a hydrogen atom or a substituted or unsubstituted C1 to 6 alkyl group; the partial structure —Y—X— represents a group represented by *—N(Rb)—C(═X1)—**; X1 each independently represents an oxygen atom or a sulfur atom; Rb represents hydrogen atom or the like; where * indicates a binding position to the carbon atom having two R1, and ** indicates a binding position to Z; and Z represents a substituted or unsubstituted methylene group, or a substituted or unsubstituted dimethylene group.] An object of the present invention is to provide an industrially easily available hatching factor on Globodera pallida larvae, a control agent and a control method using the same. The Globodera pallida control agent of the present invention contains, as an active ingredient, at least one selected from a compound of formula (I) below, a stereoisomer thereof, and a salt thereof [wherein Ar represents a substituted or unsubstituted phenyl group or the like; R1 each independently represents a group such as a substituted or unsubstituted C1 to 6 alkyl group and a substituted or unsubstituted C2 to 6 alkenyl group; R2 represents a hydrogen atom or a substituted or unsubstituted C1 to 6 alkyl group; the partial structure —Y—X— represents a group represented by *—N(Rb)—C(═X1)—**; X1 each independently represents an oxygen atom or a sulfur atom; Rb represents hydrogen atom or the like; where * indicates a binding position to the carbon atom having two R1, and ** indicates a binding position to Z; and Z represents a substituted or unsubstituted methylene group, or a substituted or unsubstituted dimethylene group.]

IPC Classes  ?

• A01N 43/18 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with sulfur as the ring hetero atom
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01N 43/10 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with sulfur as the ring hetero atom
• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
• A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01P 5/00 - Nematocides

Abstract

An object of the present invention is to provide a separation system and a separation method that can separate deuterium from a fluid containing light hydrogen and deuterium with high separation efficiency while suppressing equipment deterioration. The present invention provides a separation system including a plurality of separation devices connected in series; each of the plurality of separation devices includes an electrolyte membrane to which an anode catalyst layer and a cathode catalyst layer are provided; a first inflow passage through which a first fluid containing light hydrogen and deuterium flows in, and a first outflow passage through which a second fluid having a lower deuterium content than that of the first fluid flows out are connected to an anode flow passage, a second inflow passage through which a third fluid flows into and a second outflow passage through which a fourth fluid containing light water and heavy water flows out are connected to a cathode flow passage; at least a separation device provided at the most upstream side among the plurality of separation devices is a first separation device into which a gas containing water vapor flows as a third fluid, and from which the third fluid and deuterium that has moved from the anode catalyst layer into the cathode catalyst layer are discharged as the fourth fluid.

IPC Classes  ?

• B01D 59/40 - Separation by electrochemical methods by electrolysis
• B01D 59/42 - Separation by electrochemical methods by electromigrationSeparation by electrochemical methods by electrophoresis
• C25B 1/01 - Products
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 9/70 - Assemblies comprising two or more cells

Abstract

The objective of the present invention is to provide a method for producing a layered composite metal oxide crystal material, which can be utilized as a positive electrode material for a lithium ion secondary battery or the like, in a milder condition, and methods for producing a positive electrode and a lithium ion secondary battery using the above method. The method for producing a layered composite metal oxide crystal material according to the present invention, wherein the layered composite metal oxide crystal material comprises a composite metal oxide represented by the formula: LixMOy wherein M is 1 or 2 or more of transition metals, and a part of the M may be substituted with Al and/or Mg, x is the number of 1 or more and 2 or less, y is the number of 2 or more and 3 or less, a value of x+n is 2×y, wherein n is an average valence of the transition metal M, is characterized in comprising the step of calcining a mixture comprising a monovalent anion salt of lithium, a monovalent anion salt of sodium and/or potassium, and a monovalent anion salt of the transition metal at 150° C. or higher and 400° C. or lower in the presence of a water molecule and oxygen.

IPC Classes  ?

• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• C01G 51/00 - Compounds of cobalt
• C01G 53/00 - Compounds of nickel
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0587 - Construction or manufacture of accumulators having only wound construction elements, i.e. wound positive electrodes, wound negative electrodes and wound separators

Abstract

A slide number estimation apparatus (2000) acquires a slide image (30). The slide image (30) an image of a specimen slide (20) obtained from a tissue piece (10) of a subject. The slide number estimation apparatus (2000) estimates the number of tumor cells included in a region of interest (22) of the specimen slide (20) corresponding to the obtained slide image (30) using the slide image (30). The slide number estimation apparatus (2000) estimates the number of the specimen slides (20) to be obtained from the tissue piece (10) for conducting a predetermined test based on the estimated number of tumor cells.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

A compound represented by Formula (1), Formula (2), or Formula (3), or a salt thereof, or a solvate thereof: A compound represented by Formula (1), Formula (2), or Formula (3), or a salt thereof, or a solvate thereof: wherein R1, R2, and R3 are the same or different and each represent a hydrazine group, an N-hydroxy-acetylamino group, or an N-hydroxy-formylamino group.

IPC Classes  ?

• C07C 291/10 - Isocyanides
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics

Abstract

The present invention provides a method for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity, and a kit for quantitatively detecting virus-derived RNA and/or DNA in an environmental sample or a fecal sample with high sensitivity.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

A copper chelating agent that contains at least one compound selected from the group consisting of a compound represented by Formula (1), a compound represented by Formula (2), a compound represented by Formula (3), a compound represented by Formula (4), a salt thereof, and a solvate thereof: A copper chelating agent that contains at least one compound selected from the group consisting of a compound represented by Formula (1), a compound represented by Formula (2), a compound represented by Formula (3), a compound represented by Formula (4), a salt thereof, and a solvate thereof:

IPC Classes  ?

• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61P 39/04 - Chelating agents

Abstract

[Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections. [Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections. [Resolution Means] Provided is an antiviral agent and the like, made of: the compound represented by general formula (1) or (2) below [R1 being —(CH2)n1—Z1—R11 2 r —CH—(—Z1—R11,)(n1 being 0 or 1; Z1 being a single bond, —O—, —NH—, —S—, —SO—, —SO2—,SO—CO—, —CO—O—, or —CH═N—O—; R11 being a hydrogen atom, an alkyl group having 1 to 6 carbons, —NR12 R13, —N3,—NO2,—CN, —CH2—CO—O—R14, or a five- or six-membered heterocyclic group including a nitrogen atom; R12 and R13 each independently being a hydrogen atom or an alkyl group having 1 to 6 carbons; and R14 being a hydrogen atom or an alkyl group having 1 to 6 carbons], a derivative thereof, a salt of these compounds, or a solvate thereof. [Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections. [Resolution Means] Provided is an antiviral agent and the like, made of: the compound represented by general formula (1) or (2) below [R1 being —(CH2)n1—Z1—R11 2 r —CH—(—Z1—R11,)(n1 being 0 or 1; Z1 being a single bond, —O—, —NH—, —S—, —SO—, —SO2—,SO—CO—, —CO—O—, or —CH═N—O—; R11 being a hydrogen atom, an alkyl group having 1 to 6 carbons, —NR12 R13, —N3,—NO2,—CN, —CH2—CO—O—R14, or a five- or six-membered heterocyclic group including a nitrogen atom; R12 and R13 each independently being a hydrogen atom or an alkyl group having 1 to 6 carbons; and R14 being a hydrogen atom or an alkyl group having 1 to 6 carbons], a derivative thereof, a salt of these compounds, or a solvate thereof.

IPC Classes  ?

• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided is a composition for promotion of the regeneration of the nucleus pulposus of an intervertebral disc, said composition comprising a low endotoxin monovalent metal salt of alginic acid and mesenchymal stem cells. In particular, the composition of the present invention promotes the regeneration of the nucleus pulposus of an intervertebral disc via activation of nucleus pulposus cells by human bone marrow-derived high-purity mesenchymal stem cells and/or differentiation of human bone marrow-derived high-purity mesenchymal stem cells into nucleus pulposus cells.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

An object is to prevent eavesdropping in quantum key distribution. A decoding unit decodes a quantum signal incident thereinto. A plurality of detect photons of the decoded quantum signal output from the decoding unit. A signal processing unit detects bits of the decoded quantum signal based on photon detection results of the plurality of detectors. A control unit perform switching processing by switching destinations to which two decoded quantum signals corresponding to one encoding basis are output between the plurality of detectors, and switching the bits detected by the signal processing unit based on the respective photon detection results of the plurality of detectors.

IPC Classes  ?

• H04L 9/08 - Key distribution
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

A heat-resistant alloy contains Y, a content of Ni is a content of Ni is 58.0 mass % or greater, a content of Cr is 20.0 mass % or greater and 23.0 mass % or less, a content of Mo is 8.0 mass % or greater and 10.0 mass % or less, a content of Nb is 3.15 mass % or greater and 4.15 mass % or less, a content of O is 0.002 mass % or greater and 0.1 mass % or less, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.

IPC Classes  ?

• C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• C22C 1/04 - Making non-ferrous alloys by powder metallurgy
• C22F 1/10 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon

Abstract

The present invention provides a lipid nanoparticle and the like containing a pH-sensitive cationic lipid represented by formula (1) (in formula (1), R1 and R2 are each independently a straight-chain C10-14 alkyl group, a straight-chain C10-20 alkenyl group having one or two unsaturated bonds, or —CH(R5)(R6)(where R5 and R6 are each independently a straight-chain C5-10 alkyl group); p represents an integer of 3-8; and R3 and R4 are each independently a methyl group or an ethyl group]. The present invention provides a lipid nanoparticle and the like containing a pH-sensitive cationic lipid represented by formula (1) (in formula (1), R1 and R2 are each independently a straight-chain C10-14 alkyl group, a straight-chain C10-20 alkenyl group having one or two unsaturated bonds, or —CH(R5)(R6)(where R5 and R6 are each independently a straight-chain C5-10 alkyl group); p represents an integer of 3-8; and R3 and R4 are each independently a methyl group or an ethyl group].

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a peptide that consists of an amino acid sequence with 20 or fewer residues containing at least one amino acid sequence selected from the group consisting of the amino acid sequence represented in SEQ ID NO: 1, the amino acid sequence represented in SEQ ID NO: 2 and the amino acid sequence represented in SEQ ID NO: 38, the peptide having an activity to inhibit proliferation of a tumor cell or having an activity to inhibit binding between an epidermal growth factor receptor and a signal-transducing adaptor family member-2 (STAP-2); a peptide with a cell-penetrating peptide added to a terminus of the above peptide with or without a linker sequence interposed between the cell-penetrating peptide and the terminus; and pharmaceutical compositions containing any of these peptides.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 35/00 - Antineoplastic agents

Abstract

A printed board coil forms a coil with a plurality of turns, each formed by stacking a first layer having a first winding pattern and a second layer having a second winding pattern while having an insulation layer intervening therebetween. The first layers and the second layers are used for forming each of the coils. The coils are stacked having each of the insulation layers intervening between the coils by arranging the first layer and the second layer alternately in the stacking direction of the respective layers. The coils are connected in parallel to one another.

IPC Classes  ?

• H01F 17/00 - Fixed inductances of the signal type
• H01F 27/28 - CoilsWindingsConductive connections
• H05K 1/16 - Printed circuits incorporating printed electric components, e.g. printed resistor, capacitor, inductor

Abstract

The present invention relates to a method of producing cancer stem cells that comprises culturing a living cell population containing cancer cells in the presence of a gel substance to obtain a living cell population containing cancer stem cells, wherein the gel substance is a material that induces expression of osteopontin in at least a portion of cells contained in the living cell population. Moreover, the present invention relates to an agent for inducing conversion of cancer cells to cancer stem cells that comprises a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population. The gel substance is a synthetic polymer gel composed of, for example, double network gel, PNaSS gel, PCDME gel, PA gel, PAMPS gel, PDMA gel or PAAc gel. The present invention provides means and a method that enable the preparation of cancer stem cells in a relatively short period of time and at a relatively low culturing cost without requiring expensive equipment.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/095 - Stem cellsProgenitor cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

4)  (B)

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

A dielectric composition comprises a crystal of an oxynitride. A peak attributed to absence of a center of symmetry of the crystal of the oxynitride is detected by Raman spectroscopy of the dielectric composition within a Raman shift range of 500 cm−1 or less.

IPC Classes  ?

• C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• C23C 16/515 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges using pulsed discharges

Abstract

A light irradiation device includes a tube including a tube main body and a light emitting portion, a plurality of wiring boards disposed inside the light emitting portion and including a plurality of light emitting elements disposed at an equal interval mounted, an anode lead wire for connecting an anode terminal of each of the wiring boards to a power source, and a cathode lead wire for connecting a cathode terminal of each of the wiring boards to the power source. In the light emitting portion, a central lumen and surrounding lumens that are arrayed at a 90° interval around the central lumen are formed. The wiring boards are disposed in the respective surrounding lumens with the light emitting elements arrayed along a longitudinal direction of the light emitting portion.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

Disclosed is a method for obtaining information on von Willebrand factor (VWF), comprising the following steps: denaturing, with urea, VWF contained in a biological sample; fluorescently labeling the denatured VWF using a capturing agent that comprises a fluorescent substance and binds to the denatured VWF; and obtaining information on the size of the fluorescently-labeled VWF by fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention provides a method of culturing an alga that enables practical realization of low-cost and space-saving production of biofuels and bioenergy by culturing the alga using a reaction tank equipped with a digestive solution tank comprising digestive solution containing high concentration of nutrient salts, a membrane with a pore size of 0.45 µm or less and a culture tank comprising culture solution and the alga, which comprises consuming the nutrient salts by the alga in the culture tank to maintain the difference in concentration the nutrient salts between the digestive solution tank and the culture tank and supplying the nutrient salts contained in the digestive solution through the membrane into the culture solution by the diffusion depending on the concentration difference as well as an alga culture system therefor.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 61/14 - UltrafiltrationMicrofiltration
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• B01D 61/24 - Dialysis

Abstract

A method for making a functional structural body includes a skeletal body of a porous structure composed of a zeolite-type compound, and at least one type of metallic nanoparticles present in the skeletal body, the skeletal body having channels connecting with each other, the metallic nanoparticles being present at least in the channels of the skeletal body.

IPC Classes  ?

• B01J 29/14 - Iron group metals or copper
• B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 29/064 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof containing iron group metals, noble metals or copper
• B01J 29/068 - Noble metals
• B01J 29/072 - Iron group metals or copper
• B01J 29/076 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/08 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y
• B01J 29/10 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y containing iron group metals, noble metals or copper
• B01J 29/12 - Noble metals
• B01J 29/16 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/18 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type
• B01J 29/20 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type containing iron group metals, noble metals or copper
• B01J 29/22 - Noble metals
• B01J 29/24 - Iron group metals or copper
• B01J 29/26 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 29/42 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11 containing iron group metals, noble metals or copper
• B01J 29/44 - Noble metals
• B01J 29/46 - Iron group metals or copper
• B01J 29/48 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11 containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/60 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the type L
• B01J 29/61 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the type L containing iron group metals, noble metals or copper
• B01J 29/62 - Noble metals
• B01J 29/63 - Iron group metals or copper
• B01J 29/64 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the type L containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/65 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38
• B01J 29/66 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing iron group metals, noble metals or copper
• B01J 29/67 - Noble metals
• B01J 29/68 - Iron group metals or copper
• B01J 29/69 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
• B01J 29/72 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing iron group metals, noble metals or copper
• B01J 29/74 - Noble metals
• B01J 29/76 - Iron group metals or copper
• B01J 29/78 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 35/23 - Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/40 - Catalysts, in general, characterised by their form or physical properties characterised by dimensions, e.g. grain size
• B01J 35/50 - Catalysts, in general, characterised by their form or physical properties characterised by their shape or configuration
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• B01J 37/18 - Reducing with gases containing free hydrogen
• C01B 39/02 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereofDirect preparation thereofPreparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactantsAfter-treatment thereof
• F01N 3/28 - Construction of catalytic reactors

Abstract

A problem of the present invention is to provide a diagnostic biomarker of nonalcoholic steatohepatitis (NASH) useful for differentiation of simple steatosis (SS) from NASH and use thereof. Specifically, the present invention relates to a diagnostic biomarker of nonalcoholic steatohepatitis used to differentiate nonalcoholic steatohepatitis from simple steatosis comprising the oxidized apolipoprotein A-I (ApoA-I) modified by dioxidation of the 72nd tryptophan in the ApoA-I consisting of the amino acid sequence as shown in SEQ ID NO: 1.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

A common mode filter circuit comprises a common mode transformer unit, an inverter, and a capacitor unit. Each of the first common mode transformer, the second common mode transformer, and the third common mode transformer comprises a first secondary wound wire, a second secondary wound wire, a third secondary wound wire, and a primary wound wire. A ratio of a number of turns of the primary wound wire to a number of turns of the first secondary wound wire, a ratio of a number of turns of the primary wound wire to a number of turns of the second secondary wound wire, and a ratio of a number of turns of the primary wound wire to a number of turns of the third secondary wound wire are each 3:1 in each of the first common mode transformer, the second common mode transformer, and the third common mode transformer.

IPC Classes  ?

• H03H 7/01 - Frequency selective two-port networks
• H01F 27/28 - CoilsWindingsConductive connections
• H01F 27/29 - TerminalsTapping arrangements
• H02P 27/06 - Arrangements or methods for the control of AC motors characterised by the kind of supply voltage using variable-frequency supply voltage, e.g. inverter or converter supply voltage using DC to AC converters or inverters

Abstract

A method for producing a cancer cell aggregate having certain properties, screening a drug for preventing and/or treating cancer, and determining anoikis resistance in epithelial cancer cells. The method includes culturing cells using a cell culture substrate having a base material and a biocompatible polymer layer. The cell culture substrate has rough sections not covered with the biocompatible polymer layer on the surface of the cell culture substrate. Each of the rough sections has a shape of a spot with a diameter of 20-100 μm, or a groove with a width of 3-30 μm with an end part of the rough section being optionally connected to another rough section. A distance between two adjacent rough sections is at least 10 μm or more, and the rough section has an uneven structure with a height ranging from 20 nm to 200 nm on the surface.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12N 5/09 - Tumour cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A solution-searching system encompasses an output adjustment unit having N signal adjustment circuits for converting provisional output-adjustment signals into final output-adjustment signals, 2N data generation units for generating binary data, 2N data conversion units which convert the binary data into information, a fluctuation setting unit for suppling bias probabilities to the signal adjustment circuits, fluctuation probabilities to the data generation units, and threshold values to the data conversion units, setting occurrence-frequencies of the binary data for making an occurrence-frequency of a specific variable, and a feedback control unit for determining whether an optimal solution has been found based on the information converted by the data conversion units and search-problem information preliminarily entered, by repeating transmission of the final output-adjustment signals to the output adjustment units, if the optimal solution has not been found.

IPC Classes  ?

• G06F 30/3323 - Design verification, e.g. functional simulation or model checking using formal methods, e.g. equivalence checking or property checking

Abstract

An object of the invention is to improve reliability of an annotation. A collation apparatus includes: a grouping processing unit configured to group, based on each explanatory variable of a sample group, the sample group into a first group indicating a first classification and a second group indicating a second classification having a lower evaluation than the first classification; a collation unit configured to collate the classification of the first group and the second group that are obtained by the grouping processing unit with a classification identified by each objective variable of the sample group; and an output unit configured to output a collation result obtained by the collation unit.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

A method for producing an organometallic nucleophile includes reacting an organohalide and a metal or metal compound with each other by a mechanochemical process in the presence of an ether compound in an amount of 0.5 to 10.0 equivalents relative to 1 equivalent of the organohalide. By utilizing the method, a method for producing an organometallic nucleophile can be performed without using a large-scale apparatus, a reaction method for reactions between an organometallic nucleophile and various organic electrophiles can be performed by an efficient and simplified means, and a simplified method for producing an organometallic nucleophile can be performed with high reactivity.

IPC Classes  ?

• C07F 13/00 - Compounds containing elements of Groups 7 or 17 of the Periodic Table
• C07F 3/02 - Magnesium compounds
• C07B 49/00 - Grignard reactions

Abstract

A semiconductor optical device includes a substrate formed of silicon and having a first optical waveguide and a semiconductor element formed of a III-V compound semiconductor and having a second optical waveguide, the semiconductor element being bonded to an upper surface of the substrate. The first optical waveguide and the second optical waveguide form a directional coupler.

IPC Classes  ?

• H01S 5/10 - Construction or shape of the optical resonator
• H01S 5/22 - Structure or shape of the semiconductor body to guide the optical wave having a ridge or a stripe structure
• H01S 5/343 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser

Abstract

An information processing system includes a storage, an interface device, and a computing circuit. The storage stores a database, in which spectrum data concerning light from a light source and a measurement condition data at a time of measurement of the light are associated with a plant status data concerning growth of a plant and/or a harvest data concerning a harvest of the plant. The interface device receives an input of a user measurement condition which is to be applied at a time of measurement of the plant by a user and which includes data concerning angles at the time of measurement and data concerning a plant status and/or a harvest to be predicted. The computing circuit determines at least two wavelengths contained in the light from the light source to be measured under the user measurement condition by referring to the database based on the user measurement condition.

IPC Classes  ?

• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 21/03 - Cuvette constructions

Abstract

Provided are a method for acquiring a value relating to a triglyceride metabolic capacity of a subject within a shorter period of time compared to conventional nuclear medicine methods, and a test reagent and a test kit that are to be used in the acquisition method. This problem can be solved by an acquisition method of a value relating to the triglyceride metabolic capacity in leucocytes of a subject, said method comprising: a first step of mixing, in vitro, a fatty acid compound labeled with a fluorescent substance with leucocytes collected from the subject and thus bringing the fatty acid labeled with the fluorescent substance into contact with the leucocytes, wherein the fatty acid compound contains a fatty acid residue, the fatty acid residue has 8-26 carbon atoms, and a part of hydrogen atoms constituting the fatty acid residue, excluding a terminal methyl group of the fatty acid residue, may be substituted by an alkyl group having 1-3 carbon atoms; and a second step of acquiring, as the value relating to the triglyceride metabolic capacity, a measured fluorescence intensity that is derived from the fluorescent label in the leucocytes.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings

Abstract

The spectroscopic measuring instrument includes: a spectrometer to make measurement of a reflection spectrum of an object relative to a light source and output measurement information representing a result of the measurement; a shadow projector including obstacle(s) to allow light from the light source to cast shadow(s) on an object surface; an imaging device to output image information representing an image of an imaging area including the object surface; a storage interface removably connectable to a computer readable medium; and a processing device. The processing device is connected to the spectrometer, the imaging device and the storage interface, and performs a measurement process of storing the measurement information from the spectrometer and the image information from the imaging device in the computer readable medium connected to the storage interface.

IPC Classes  ?

• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01J 3/28 - Investigating the spectrum

Abstract

A polypeptide that comprises the amino acid sequence of SEQ ID NO: 1 and has a function of delivering a substance into cells, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2 and has a function of degrading a nucleic acid molecule, a polypeptide that comprises the amino acid sequence of SEQ ID NO: 3 and has a function of degrading a nucleic acid molecule and a function of intranuclearly migrating the same, polynucleotides encoding the respective polypeptides, and transformed cells containing the respective polynucleotides.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

An electrochemical sensor is used in a state of being immersed in water to be inspected for water quality inspection. The electrochemical sensor includes a working electrode, a reference electrode, a first counter electrode, and a second counter electrode. The working electrode, the reference electrode, the first counter electrode, and the second counter electrode are electrically isolated from each other.

IPC Classes  ?

• G01N 27/416 - Systems
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 33/18 - Water

Abstract

A method for evaluating the progression of hepatic fibrosis in non-alcoholic steatohepatitis, said method comprising measuring the amount of a sugar chain having a structure represented by formula (I) and/or a precursor sugar chain of the biosynthesis of a sugar chain having a structure represented by formula (I) in a sample.

IPC Classes  ?

• G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose

Abstract

An object of the present invention is to provide a hydrogen permeable material having excellent hydrogen permeability. Another object of the present invention is to provide a composite member and a fuel cell including the hydrogen permeable material. The hydrogen permeable material comprises a perovskite type compound represented by the following general formula (1a). In another embodiment, the hydrogen permeable material comprises a hydrogen-containing perovskite type compound, which is the perovskite type compound represented by the general formula (1a) with introduced hydride ion (H−). Wherein M is at least one alkaline earth metal selected from the group consisting of Ba, Sr and Ca, x is a numerical value of 0 or more and 0.3 or less, y is a numerical value of more than 0 and 0.75 or less, w is a value at which an average valence of In is +1.0 or more and +2.5 or less, and y≥w. An object of the present invention is to provide a hydrogen permeable material having excellent hydrogen permeability. Another object of the present invention is to provide a composite member and a fuel cell including the hydrogen permeable material. The hydrogen permeable material comprises a perovskite type compound represented by the following general formula (1a). In another embodiment, the hydrogen permeable material comprises a hydrogen-containing perovskite type compound, which is the perovskite type compound represented by the general formula (1a) with introduced hydride ion (H−). Wherein M is at least one alkaline earth metal selected from the group consisting of Ba, Sr and Ca, x is a numerical value of 0 or more and 0.3 or less, y is a numerical value of more than 0 and 0.75 or less, w is a value at which an average valence of In is +1.0 or more and +2.5 or less, and y≥w. M1-xZr1-yInyO3-x-0.5y-2  (1a)

IPC Classes  ?

• C01G 25/02 - Oxides
• C01G 25/00 - Compounds of zirconium
• H01M 8/1253 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides the electrolyte containing zirconium oxide
• H01M 8/126 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides the electrolyte containing cerium oxide

Abstract

A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor: A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor: A method for decomposing a compound represented by Formula (1) includes irradiating the compound with X-rays in a presence of an electron donor: wherein R111, R121, R131, and R141 each independently represent a monovalent organic group; p, q, r, and s each independently represent an integer of 0 or 1 to 4; in the case where two or more R111, R121, R131, and R141 are present, they may be identical to or different from one another or may be bonded to one another to form a ring; A101 represents a monovalent organic group; and A102 represents a hydrogen atom or a monovalent organic group). In the method, a photosensitive dye can be decomposed using an energy beam which can penetrate deeper into a living body than near-infrared light and activate the photosensitive dye.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

A composition for activating cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. A composition for CTL activation for proliferation of cytotoxic T lymphocytes (CTLs) containing a spirulina extract is provided. Moreover, a pharmaceutical composition for CTL activation or a food or a drink for CTL activation containing the composition for CTL activation is provided.

IPC Classes  ?

• A61K 35/748 - Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 17/00 - Drugs for dermatological disorders
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 35/00 - Antineoplastic agents

Abstract

An aluminum member (1) includes: a base material (2) composed of aluminum or an aluminum alloy; and an anodic oxide film (3) formed on a surface of the base material. The anodic oxide film includes: an amorphous layer (31), which is composed of an amorphous aluminum oxide and is formed on the base material (2); and a crystal layer (32), which is composed of a crystalline aluminum oxide and is formed on the amorphous layer (31). The aluminum member (1) can be obtained by forming the anodic oxide film (3) on the base material (2) by performing an anodization process on the base material (2) in an electrolytic solution, which contains boron atoms and has a pH of 7.0-12.0.

IPC Classes  ?

• C25D 11/06 - Anodisation of aluminium or alloys based thereon characterised by the electrolytes used
• C25D 11/14 - Producing integrally coloured layers

Abstract

The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

A catalyst structure for synthesis gas production of a synthesis gas that contains carbon monoxide and hydrogen, the catalyst structure being provided with a carrier that has a porous structure, while being configured from a zeolite type compound; first catalyst particles that contain one or more iron group elements which are selected from the group consisting of nickel (Ni), iron (Fe) and cobalt (Co); and second catalyst particles that contain one or more platinum group elements which are selected from the group consisting of platinum (Pt), palladium (Pd), rhodium (Rh) and ruthenium (Ru). The catalyst structure for synthesis gas production has passages in communication with each other within the carrier. The first catalyst particles are present at least in the passages of the carrier; and the second catalyst particles are present at least either inside the carrier or on the outer surface of the carrier.

IPC Classes  ?

• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 35/10 - Solids characterised by their surface properties or porosity
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B01J 37/16 - Reducing
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

To provide a functional structural body that can realize a long life time by suppressing the decline in function of the functional substance and that can attempt to save resources without requiring a complicated replacement operation, and to provide a method for making the functional structural body. The functional structural body (1) includes a skeletal body (10) of a porous structure composed of a zeolite-type compound, and at least one functional substance (20) present in the skeletal body (10), the skeletal body (10) has channels (11) connecting with each other, and the functional substance is present at least in the channels (11) of the skeletal body (10).

IPC Classes  ?

• B01J 29/76 - Iron group metals or copper
• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 29/064 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof containing iron group metals, noble metals or copper
• B01J 29/068 - Noble metals
• B01J 29/072 - Iron group metals or copper
• B01J 29/076 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/08 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y
• B01J 29/10 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y containing iron group metals, noble metals or copper
• B01J 29/12 - Noble metals
• B01J 29/14 - Iron group metals or copper
• B01J 29/16 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/18 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type
• B01J 29/20 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type containing iron group metals, noble metals or copper
• B01J 29/22 - Noble metals
• B01J 29/24 - Iron group metals or copper
• B01J 29/26 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 29/42 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11 containing iron group metals, noble metals or copper
• B01J 29/44 - Noble metals
• B01J 29/46 - Iron group metals or copper
• B01J 29/48 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11 containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/60 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the type L
• B01J 29/61 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the type L containing iron group metals, noble metals or copper
• B01J 29/62 - Noble metals
• B01J 29/63 - Iron group metals or copper
• B01J 29/64 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the type L containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/65 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38
• B01J 29/66 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing iron group metals, noble metals or copper
• B01J 29/67 - Noble metals
• B01J 29/68 - Iron group metals or copper
• B01J 29/69 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the ferrierite type, e.g. types ZSM-21, ZSM-35 or ZSM-38 containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
• B01J 29/72 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing iron group metals, noble metals or copper
• B01J 29/74 - Noble metals
• B01J 29/78 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
• B01J 35/23 - Catalysts, in general, characterised by their form or physical properties characterised by their non-solid state in a colloidal state
• B01J 35/56 - Foraminous structures having flow-through passages or channels, e.g. grids or three-dimensional monoliths
• B01J 35/64 - Pore diameter
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam

Abstract

It is an object of the present invention to provide a Japanese encephalitis preventive agent and a Japanese encephalitis vaccine agent, which are capable of imparting sufficient immunity to humans, even if these agents are used at a lower dose than the dose of a Japanese encephalitis vaccine for subcutaneous injection, or at a smaller number of administrations than the number of administrations of a Japanese encephalitis vaccine for subcutaneous injection. According to the present invention, provided is a Japanese encephalitis preventive agent, comprising a microneedle array having a sheet portion and a plurality of needle portions present on the upper surface of the sheet portion, wherein the aforementioned needle portions contain or carry an inactivated Japanese encephalitis virus.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/12 - Viral antigens
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

A rod group includes a plurality of first rods that has an arcuate first curve, the first rods having mutually different lengths; and a plurality of second rods that has an S-shaped second curve, the second rods having mutually different lengths. The first rods and the second rods have shapes for treatment of scoliosis by (i) guiding the postoperative apex of the thoracic kyphosis to be located at the thoracic vertebrae T6 to T8, and (ii) guiding a postoperative apex of the thoracic kyphosis to be located at a position different from a preoperative apex of the thoracic kyphosis and the second rod each have a shape extending along an anatomically normal spinal column arrangement.

IPC Classes  ?

• A61B 17/70 - Spinal positioners or stabilisers, e.g. stabilisers comprising fluid filler in an implant

Abstract

A parent-and-child health study assistance system includes a data management section managing health study data used for a health study of at least one of a parent and a child in a family including a user as a family member, a level calculation section calculating a contribution level for the health study of the user based on input of the health study data, an incentive provision section providing the user with an incentive used as a profit corresponding to the contribution level, in conjunction with input of the health study data, an access control section managing an access authority to access the health study data, and an analysis result provision section providing an analysis result of analysis processing using the health study data.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G06Q 30/0208 - Trade or exchange of goods or services in exchange for incentives or rewards
• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules

Abstract

A treatment device that shortens the time period until healing is determined even when a bone defect or a root apex lesion is generated in an apical area. The treatment device includes a file holder, a high-frequency signal generating circuit, and a control circuit. The file holder holds a file to be located in the site to be treated. The high-frequency signal generating circuit passes a high frequency current through the file. The control circuit controls a frequency of the high frequency current to be passed through the file from the high-frequency signal generating circuit. The control circuit controls the frequency of the high frequency current to be passed through the file within a range of 1.001 MHz to 11.700 MHz.

IPC Classes  ?

• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 1/06 - Electrodes for high-frequency therapy
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61C 5/40 - Implements for surgical treatment of the roots or nerves of the teethNerve needlesMethods or instruments for medication of the roots

Abstract

Disclosed is oxide-containing copper fine particles including Cu64O and optionally Cu2O and coated with a carboxylic acid, wherein a mass ratio of Cu64O to a total mass of Cu, Cu64O and Cu2O is 0.5 to 2.0% by mass.

IPC Classes  ?

• B22F 1/102 - Metallic powder coated with organic material
• B22F 9/04 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
• B22F 7/04 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite layers with one or more layers not made from powder, e.g. made from solid metal

Abstract

Disclosed is a method for producing a mono-cross-coupled aromatic compound (3-1) having one less leaving group than an aromatic compound (1) having at least two leaving groups, the method comprising: preparing the aromatic compound (1) having at least two leaving groups; preparing a compound (2) capable of undergoing a cross-coupling reaction selected from an aromatic boronic acid (2-1), an aromatic amino compound (2-2), a diboronic acid ester (2-3), an aromatic compound (2-4) having a hydroxyl group and an aromatic compound (2-5) having a thiol group; and performing a cross-coupling reaction of the aromatic compound (1) having at least two leaving groups with the compound (2) in the presence of a palladium catalyst and a base, in the absence of a solvent.

IPC Classes  ?

• C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 17/263 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
• C07C 1/30 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero atoms by splitting-off the elements of hydrogen halide from a single molecule
• C07C 17/269 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of only halogenated hydrocarbons
• C07D 333/16 - Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
• C07D 333/22 - Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
• C07D 333/56 - Radicals substituted by oxygen atoms
• C07C 1/32 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen

Abstract

An analysis device in a parent-child health management system receives a sensor output from a sensor terminal and an answer to a questionnaire from a user terminal. At least one of parent's life information and child's life information is analyzed based on the answer to the questionnaire to generate a life information analysis result. A sensor output analysis unit generates, based on the sensor output, a sensing result including at least one of a parent-child relationship, a parent's health condition, and a child's health condition. A health estimation unit is configured to compare the life information analysis result and the sensing result with a predetermined criterion to estimate at least one of a parent-child state, a parent's state, and a child's state. An output unit is configured to select a questionnaire and advice corresponding to the estimated state and output the selected questionnaire and advice to the user terminal.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires

Abstract

A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): [in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R3 and R4 each independently represents a C1-4 alkyl group or a C2-4 alkenyl group, where, R3 and R4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C1-4 alkyl groups or C2-4 alkenyl groups may be substituted on the ring)].

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
• C07D 295/03 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms